Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-296456
Filing Date
2018-10-10
Accepted
2018-10-10 09:05:36
Documents
10
Period of Report
2018-11-29
Effectiveness Date
2018-10-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A d616630ddef14a.htm DEF 14A 787517
2 GRAPHIC g616630dsp001.jpg GRAPHIC 208526
3 GRAPHIC g616630dsp002.jpg GRAPHIC 321735
4 GRAPHIC g616630g1009075000781.jpg GRAPHIC 21190
5 GRAPHIC g616630g1009075001062.jpg GRAPHIC 17445
6 GRAPHIC g616630g1009075001296.jpg GRAPHIC 22536
7 GRAPHIC g616630g1009075001530.jpg GRAPHIC 14050
8 GRAPHIC g616630g30n56.jpg GRAPHIC 1930
9 GRAPHIC g616630g42x55.jpg GRAPHIC 27891
10 GRAPHIC g616630page28.jpg GRAPHIC 10155
  Complete submission text file 0001193125-18-296456.txt   1678666
Mailing Address 320 WAKARA WAY SALT LAKE CITY UT 84108
Business Address 320 WAKARA WAY SALT LAKE CITY UT 84108 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 0630
Type: DEF 14A | Act: 34 | File No.: 000-26642 | Film No.: 181114967
SIC: 2835 In Vitro & In Vivo Diagnostic Substances